Keros Therapeutics, Inc. cash flow statement

In fiscal 2025, Keros Therapeutics, Inc.'s operations generated $108m of cash; it spent $1.6m on capital projects, leaving free cash flow of $106m. It returned $375m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Keros Therapeutics, Inc.: cash flow statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash from operations	−16	−37	−62	−70	−125	−161	108	−48
Depreciation and amortisation	0	0	0	1	1	1	2	2
Stock-based pay	0	4	12	19	29	35	29	23
Capital spending	0	0	1	1	2	2	2	0
Free cash flow	−16	−37	−63	−71	−127	−163	106	−48
Free cash flow after stock pay	−16	−41	−75	−90	−156	−198	77	−71
Share buybacks	—	—	—	—	—	0	375	—
Shares issued	0	141	—	—	—	—	—	—

US$ millions unless shown otherwise. Fiscal quarters.

Keros Therapeutics, Inc.: cash flow statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	−31	−46	161	−30	3	−27	−4	−20
Depreciation and amortisation	0	0	0	0	0	0	0	0
Stock-based pay	9	9	9	9	4	7	6	5
Capital spending	0	0	1	1	0	0	0	0
Free cash flow	−31	−46	161	−30	3	−27	−4	−21
Free cash flow after stock pay	−40	−55	152	−39	−1	−35	−10	−26

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ALEC vs KROS KROS vs LCTX KROS vs PRQR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Keros Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Keros Therapeutics, Inc.